ArticleAging2020
Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Identification and validation of autophagy‑related genes in hypertrophic cardiomyopathy.Experimental and therapeutic medicine · 2024Article
- Calcium signaling in mitochondrial intermembrane space.Biochemical Society transactions · 2024Review
- Mitochondrial Dysfunction: A Roadmap for Understanding and Tackling Cardiovascular Aging.Aging and disease · 2024Review
- Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration.Molecular neurodegeneration · 2024Review
- Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases.Signal transduction and targeted therapy · 2024Review
- Mitochondrial Melatonin: Beneficial Effects in Protecting against Heart Failure.Life (Basel, Switzerland) · 2024Review
- Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction.International journal of molecular sciences · 2023Review
- Mitochondrial Dysfunction in Arrhythmia and Cardiac Hypertrophy.Reviews in cardiovascular medicine · 2023Review
- Engineered small extracellular vesicle-mediated NOX4 siRNA delivery for targeted therapy of cardiac hypertrophy.Journal of extracellular vesicles · 2023Article
- Transmembrane protein 117 knockdown protects against angiotensin-II-induced cardiac hypertrophy.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Paeonol improves angiotensin II-induced cardiac hypertrophy by suppressing ferroptosis.Heliyon · 2023Article
- Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses.Exploration of targeted anti-tumor therapy · 2023Review
- Therapeutics of Extracellular Vesicles in Cardiocerebrovascular and Metabolic Diseases.Advances in experimental medicine and biology · 2023Article
- Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin.Life (Basel, Switzerland) · 2022Review
- Melatonin Prevents NaAsOAntioxidants (Basel, Switzerland) · 2022Article
- The Impact of Melatonin Supplementation and NLRP3 Inflammasome Deletion on Age-Accompanied Cardiac Damage.Antioxidants (Basel, Switzerland) · 2021Article
- Role of Melatonin in Angiotensin and Aging.Molecules (Basel, Switzerland) · 2021Review
- Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses.Cardiovascular therapeutics · 2021Article
- Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial calcium uptake 1 (MICU1) is a pivotal molecule in maintaining mitochondrial homeostasis under stress conditions. However, it is unclear whether MICU1 attenuates mitochondrial stress in angiotensin II (Ang-II)-induced cardiac hypertrophy or if it has a role in the function of melatonin. Here, small-interfering RNAs against MICU1 or adenovirus-based plasmids encoding MICU1 were delivered into left ventricles of mice or incubated with neonatal murine ventricular myocytes (NMVMs) for 48 h. MICU1 expression was depressed in hypertrophic myocardia and MICU1 knockdown aggravated Ang-II-induced cardiac hypertrophy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.